Venrock Adviser, LLC 13F holdings, Q2 2025
Holdings as of June 30, 2025 · filings on SEC EDGAR · latest filing →
Venrock Adviser, LLC disclosed 31 US equity positions worth $1.3bn in its Q2 2025 13F filing. The largest position was APGE at 27.6% of the reported book, followed by OCUL and METSERA INC. Against the Q1 2025 filing, it opened 4 new positions, added to 3 and reduced 6 among the top 31 holdings.
What did Venrock Adviser, LLC own in Q2 2025? Top 31 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2025 |
|---|---|---|---|---|---|---|---|
| 1 | APGE APOGEE THERAPEUTICS INC | Healthcare | 27.6% | $368.9m | 8,493,321 | 0% | held |
| 2 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 8.9% | $118.4m | 12,762,462 | 0% | held |
| 3 | METSERA INC | 8.0% | $106.7m | 3,750,662 | 0% | held | |
| 4 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 6.1% | $80.8m | 4,026,331 | 0% | held |
| 5 | 4XC1 KALVISTA PHARMACEUTICALS INC | 5.7% | $76.1m | 6,728,985 | 0% | held | |
| 6 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 5.0% | $67.0m | 6,596,885 | 107% | added |
| 7 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 4.1% | $54.3m | 3,882,709 | 0% | held |
| 8 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 3.5% | $46.5m | 4,148,428 | 0% | held |
| 9 | SYRE SPYRE THERAPEUTICS INC | 3.0% | $40.2m | 2,685,448 | 0% | held | |
| 10 | PHVS PHARVARIS N V | 2.7% | $36.0m | 2,047,620 | -34% | reduced | |
| 11 | COGT COGENT BIOSCIENCES INC | Healthcare | 2.6% | $34.1m | 4,755,411 | -16% | reduced |
| 12 | JBIO JADE BIOSCIENCES INC | 2.4% | $32.2m | 3,220,364 | – | new | |
| 13 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 2.4% | $31.7m | 13,969,882 | – | new |
| 14 | CDTX CIDARA THERAPEUTICS INC | 2.3% | $31.1m | 639,088 | -39% | reduced | |
| 15 | UPB UPSTREAM BIO INC | 1.9% | $25.2m | 2,295,319 | 0% | held | |
| 16 | ERAS ERASCA INC | Healthcare | 1.7% | $22.7m | 17,857,083 | 10% | added |
| 17 | CBIO CRESCENT BIOPHARMA INC. | 1.7% | $22.4m | 1,387,864 | – | new | |
| 18 | DYN DYNE THERAPEUTICS INC | Healthcare | 1.6% | $20.7m | 2,173,913 | 0% | held |
| 19 | SVRA SAVARA INC | Healthcare | 1.5% | $20.3m | 8,884,263 | 173% | added |
| 20 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 1.4% | $18.6m | 1,000,000 | -43% | reduced |
| 21 | ENGENE HOLDINGS INC | 1.4% | $18.4m | 5,046,414 | 0% | held | |
| 22 | CATBUSD ASTRIA THERAPEUTICS INC | 1.0% | $13.2m | 2,457,348 | 0% | held | |
| 23 | CGEM CULLINAN THERAPEUTICS INC | Healthcare | 0.8% | $10.4m | 1,379,965 | 0% | held |
| 24 | ABVX ABIVAX SA | 0.8% | $10.3m | 1,345,780 | 0% | held | |
| 25 | PERCEPTIVE CAP SOLUTIONS COR | 0.6% | $8.0m | 750,000 | 0% | held | |
| 26 | SEPN SEPTERNA INC | 0.4% | $5.7m | 540,453 | – | new | |
| 27 | SRZN SURROZEN INC | 0.4% | $5.7m | 632,931 | 0% | held | |
| 28 | ZURA ZURA BIO LTD | Healthcare | 0.4% | $4.9m | 4,631,216 | -8% | reduced |
| 29 | ARTV ARTIVA BIOTHERAPEUTICS INC | 0.2% | $2.4m | 1,609,569 | 0% | held | |
| 30 | CASIF CASI PHARMACEUTICALS INC | 0.1% | $1.2m | 987,259 | 0% | held | |
| 31 | TENX TENAX THERAPEUTICS INC | 0.0% | $567.7k | 98,564 | -53% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.